Enhanced normal tissue doses caused by tumour shrinkage during brachytherapy

British Journal of Radiology

Volumn 72, Issue MAY, 1999, Pages 499-501

  Dale, R G ^a   Jones, B ^b  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125;

ARTICLE; BRACHYTHERAPY; CANCER REGRESSION; GLIOMA; HALF LIFE TIME; HUMAN; MAJOR CLINICAL STUDY; RADIATION DOSE; TUMOR VOLUME;

EID: 0033012156     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr.72.857.10505017     Document Type: Article

References (6)

1. Dale RG, Jones B, Coles IP. Effect of tumour shrinkage on the biological effectiveness of permanent brachytherapy implants. Br J Radiol 1994;67:639-45.
2. Kreth FW, Faist M, Rossner R, Birg W, Volk B, Ostertag CB, et al. The risk of interstitial radiotherapy of low-grade gliomas. Radiother Oncol 1997; 43:253-60.
3. Dale RG. Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model. Br J Radiol 1989;62:241-4.
4. Dale RG, Coles IP, Deehan C, O'Donoghue JA. The calculation of integrated biological response in brachytherapy. Int J Radiat Oncol Biol Phys 1997; 38:633-42.
5. Tan LT, Romaniuk CS, Brunt J, Kingston RK, Jones B. The use of serial MRI to measure changes in tumour volume during radiotherapy for carcinoma of the cervix. In: K Faulkner, RM Harrison, B Casey, A Grellin, editors. Quantitative imaging in oncology. London: British Institute of Radiology, 1996, 150-2.
6. Dale RG, Jones B. The effect of tumour shrinkage on biologically effective dose, and possible implications for fractionated high dose-rate brachytherapy. Radiother Oncol 1994;33:125-32.